New obesity drug put to heart safety test in early trial
NCT ID NCT07229157
First seen Nov 16, 2025 · Last updated May 24, 2026 · Updated 25 times
Summary
This early-stage study checks whether maridebart cafraglutide, a drug for overweight or obesity, changes the heart's electrical activity. About 81 adults aged 18-60 will receive the drug, a placebo, or a positive control to compare effects. The main goal is to see if the drug causes any heart rhythm issues, helping ensure safety before larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fortrea Clinical Research Unit - Dallas
Dallas, Texas, 75247-4968, United States
-
Fortrea Clinical Research Unit - Daytona Beach
Daytona Beach, Florida, 32117-5116, United States
Conditions
Explore the condition pages connected to this study.